menu
    • menu
    [{"orgOrder":0,"company":"ResolutionRx","sponsor":"RespireRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"ResolutionRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ResolutionRx \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"ResolutionRx \/ ResolutionRx"},{"orgOrder":0,"company":"ResolutionRx","sponsor":"Ab Initio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"ResolutionRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ResolutionRx \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"ResolutionRx \/ ResolutionRx"}]

    Find Clinical Drug Pipeline Developments & Deals by ResolutionRx

    Menu

    ResolutionRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ResolutionRx

                            Australia arrow
                            EPSC
                            Not Confirmed

                            ResolutionRx

                            Australia arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Recipient : Ab Initio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Drona...

                            Details : The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test the new dronabinol lipid nanoparticle formulation...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            December 10, 2023

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Recipient : Ab Initio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ResolutionRx

                            Australia arrow
                            EPSC
                            Not Confirmed

                            ResolutionRx

                            Australia arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Recipient : RespireRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx ...

                            Details : Under the agreement, ResolutionRx will use and exploit the Licensed IP associated with new dronabinol formulations initially to be developed for the treatment of obstructive sleep apnea.

                            Product Name : ResolutionRx

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            September 08, 2023

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Recipient : RespireRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth